| Literature DB >> 27872848 |
Victor V Revin1, Natalia V Gromova1, Elvira S Revina1, Maria I Martynova1, Angelina I Seikina1, Nadezhda V Revina1, Oksana G Imarova2, Ilia N Solomadin1, Alexander Yu Tychkov1, Nikolai Zhelev3.
Abstract
The composition and condition of membrane lipids, the morphology of erythrocytes, and hemoglobin distribution were explored with the help of laser interference microscopy (LIM) and Raman spectroscopy. It is shown that patients with cardiovascular diseases (CVD) have significant changes in the composition of their phospholipids and the fatty acids of membrane lipids. Furthermore, the microviscosity of the membranes and morphology of the erythrocytes are altered causing disordered oxygen transport by hemoglobin. Basic therapy carried out with the use of antiaggregants, statins, antianginals, beta-blockers, and calcium antagonists does not help to recover the morphofunctional properties of erythrocytes. Based on the results the authors assume that, for the relief of the ischemic crisis and further therapeutic treatment, it is necessary to include, in addition to cardiovascular disease medicines, medication that increases the ability of erythrocytes' hemoglobin to transport oxygen to the tissues. We assume that the use of LIM and Raman spectroscopy is advisable for early diagnosis of changes in the structure and functional state of erythrocytes when cardiovascular diseases develop.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27872848 PMCID: PMC5107249 DOI: 10.1155/2016/3429604
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Change in the amount of phospholipids and lysophospholipids in red blood cells membranes of patients with stable angina (SA) and stable angina with hypertension (HT): µg P PLind/mg P PLgen. p < 0.01; p < 0.05.
Figure 2Change in the amount of phospholipids and lysophospholipids (µg P PLind/mg P PLgen) and free fatty acids (µg P PLind/mg P PLgen) in erythrocytic membranes of patients with stable angina (SA) before and after treatment. p < 0.05.
The change in saturation ratio (R sat) of individual phospholipid fractions in erythrocytic membranes of patients with stable angina (SA) and SA with hypertension (HT) on the background of treatment (means ± SD).
| Variants of experiments |
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Donors | 1.05 ± 0.021 | 1.3 ± 0.038 | 1.7 ± 0.021 | 1.2 ± 0.023 | 1.2 ± 0.021 | 1.95 ± 0.022 | 1.1 ± 0.02 |
| Patients with SA before treatment | 1.65 ± 0.06 | 2.86 ± 0.069 | 3.23 ± 0.055 | 1.8 ± 0.051 | 2.34 ± 0.056 | 2.71 ± 0.69 | 2.26 ± 0.094 |
| Patients with SA+HT before treatment | 1.77 ± 0.067 | 3.92 ± 0.066 | 3.84 ± 0.05 | 2.24 ± 0.044 | 2.87 ± 0.058 | 2.89 ± 0.061 | 3.21 ± 0.062 |
| Patients with SA after treatment | 1.29 ± 0.063 | 2.09 ± 0.082 | 2.58 ± 0.075 | 1.49 ± 0.06 | 1.62 ± 0.066 | 2.45 ± 0.089 | 1.58 ± 0.076 |
| Patients with SA+HT after treatment | 1.45 ± 0.047 | 3.02 ± 0.079 | 3.26 ± 0.026 | 1.93 ± 0.078 | 1.95 ± 0.078 | 2.64 ± 0.079 | 2.41 ± 0.043 |
Reliability in relation to donors' indicators.
Reliability in relation to pretreatment indicators at p < 0.05.
Figure 3Change in the content of lipid peroxidation products in erythrocytic membranes of patients with SA and SA on the background of hypertension (HT) in the course of treatment. p < 0.05.
Figure 43D simulation (a) and a profile (b) of human erythrocyte in norm, LIM image.
Figure 53D simulation (a) and phase profile (b) of SA patient's erythrocyte, LIM image.
Distribution of erythrocytes sizes in the course of SA patients' treatment and healthy persons (means ± SD).
| Patients groups | Indicators | ||
|---|---|---|---|
| Phase image area of erythrocyte, | Erythrocyte volume, | The mean value of optical path difference (OPD), Φmean, | |
| Donors | 110.92 ± 0.54 | 89.43 ± 3.63 | 60.92 ± 2.36 |
| SA patients before treatment | 87.35 ± 3.01 | 126.29 ± 3.15 | 108.44 ± 2.28 |
| SA+HT patients before treatment | 92.32 ± 4.77 | 109.21 ± 3.61 | 88.72 ± 4.30 |
| SA patients after treatment | 99.44 ± 2.45 | 118.47 ± 2.68 | 89.35 ± 1.92 |
| SA+HT patients after treatment | 101.30 ± 1.95 | 108.88 ± 2.04 | 80.61 ± 1.51 |
Reliability in relation to donors' indicators.
Reliability in relation to pretreatment indicators at p < 0.05.
Figure 63D simulation (a) and phase profile (b) of SA patient's erythrocyte, LIM image. Stomatocyte.
Figure 73D simulation (a) and phase profile (b) of SA patient's erythrocyte, LIM image. Spherocyte formation.
Figure 83D simulation (a) and phase profile (b) of SA+HP patients' erythrocyte, LIM image.
Changes of oxygen binding ability of hemoglobin in the course of treatment of IHD patients and healthy persons (means ± SD).
| Patients groups | Variants | |||
|---|---|---|---|---|
| Relative quantity of o-Hb in blood, rel. Un. | Relative ability of Hb to bind ligands (including O2), rel. Un. | Relative ability of Hb to isolate ligands, rel. Un. | Affinity of Hb to ligands, first of all to O2, rel. Un. | |
| Donors | 0.76 ± 0.02 | 0.65 ± 0.03 | 0.58 ± 0.02 | 1.28 ± 0.02 |
|
| ||||
| Patients before treatment | ||||
| SA patients before treatment | 0.54 ± 0.03 | 0.87 ± 0.03 | 0.31 ± 0.02 | 1.86 ± 0.04 |
| SA+HT patients before treatment | 0.45 ± 0.03 | 1.02 ± 0.03 | 0.36 ± 0.02 | 1.77 ± 0.04 |
|
| ||||
| Patients after treatment | ||||
| SA patients after treatment | 0.63 ± 0.03 | 0.73 ± 0.03 | 0.45 ± 0.03 | 1.26 ± 0.02 |
| SA+HT patients after treatment | 0.49 ± 0.08 | 0.75 ± 0.07 | 0.39+0.04 | 1.47 ± 0.04 |
Reliability in relation to donors' indicators.
Reliability in relation to pretreatment indicators at p < 0.05.